Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment

 

Management to host webcast and conference call today at 1:15 p.m. PDT/4:15 p.m. EDT

 

LA JOLLA, Calif., Aug. 10, 2016 -- Kura Oncology, Inc., (KURA) a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2016 financial results and recent business highlights. In the company’s Phase 2 trial of tipifarnib in HRAS mutant solid tumors, positive clinical activity, including objective responses, has been observed in patients with head and neck squamous cell carcinomas and patients with salivary gland cancer. Based on these responses, enrollment will be expanded to an additional seven patients.

HASBROUCK HEIGHTS, N.J., Aug. 11, 2016  -- Nymox Pharmaceutical Corporation (NYMX) is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer. Fexapotide has completed 2 long-term large Phase 3 BPH studies‎ in the U.S. No other new prostate drug injectable currently in development has previously succeeded in enrolling and completing a fully U.S. study close to the size of either of Nymox’s 2 long-term studies. In addition, no other injectable prostate enlargement drug has previously been shown to have the excellent long-term safety and efficacy profile of fexapotide.

 

Fexapotide treated BPH patients were shown to have a remarkably low incidence of ‎later development of prostate cancer after up to 7 years of follow-up at top U.S. clinical trial centers. 

Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection

IND Filing for Allogeneic Memory-Like NK Cell Cancer Immunotherapy Planned for 2016

Announced $10.3 Million Common Stock Private Placement

 

SAN DIEGO, Aug. 08, 2016 -- Fate Therapeutics, Inc. (FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the second quarter ended June 30, 2016.

 

“With the opening of enrollment in our Phase 1/2 clinical trial, we believe we are well-positioned in 2016 to complete the initial safety assessment and begin evaluating the potential of ProTmune for the prevention of life-threatening immunological conditions, including acute GvHD, in cancer patients undergoing allogeneic transplant for which there is a clear unmet and urgent medical need,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 

LUGANO, Switzerland and SAN DIEGO, Aug. 8, 2016  -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that they have entered into an exclusive licensing, development and commercialization agreement for Pracinostat, a Phase III-ready drug candidate for the treatment of acute myeloid leukemia (AML) and other potential indications. The deal provides the complementary resources from both organizations to rapidly advance Pracinostat into Phase III clinical development and expand into additional indications, including high-risk myelodysplastic syndrome (MDS).